glp1-agonists

GLP-1 Receptor Agonists

A pharmacological class of peptide drugs that activate the glucagon-like peptide-1 receptor (GLP-1R), producing coordinated effects on weight, glycemia, cardiovascular risk, and systemic inflammation. Originally developed for type-2-diabetes, the class has achieved outsized relevance in aging biology due to its demonstrated reduction in major adverse cardiovascular events (MACE) in large, well-powered RCTs — including in non-diabetic populations — and emerging evidence for anti-inflammatory effects that may intersect with the chronic-inflammation hallmark of aging. As of 2026, this is the highest-evidence pharmacological intervention class for cardiometabolic aging outcomes, though aging-specific endpoints (frailty, biological age, all-cause mortality in healthy older adults) remain untested.

This page covers the drug class as a whole. Agent-specific data live in molecules/compounds/:

• semaglutide (verified-partial, R21) — Ozempic / Wegovy / Rybelsus; weekly SC or oral; SELECT trial
• liraglutide — Victoza / Saxenda; daily SC; first long-acting GLP-1 RA (T2D 2010, obesity 2014); LEADER trial
• tirzepatide — Mounjaro / Zepbound; dual GLP-1/GIP agonist; weekly SC; SURMOUNT-1
• retatrutide — triple GLP-1/GIP/glucagon agonist; Phase 3 as of 2026
• exenatide, lixisenatide, dulaglutide — earlier-generation GLP-1 RAs; less aging-relevant trial data

Class identity and mechanism

GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1R agonists mimic this signal with modified peptides engineered for plasma half-lives of hours to days rather than the native hormone’s ~2-minute half-life.

Class-level mechanistic effects:

Mechanism	Site	Effect relevant to aging
GLP-1R agonism (pancreatic beta-cell)	Pancreas	Glucose-dependent insulin secretion; beta-cell preservation
GLP-1R agonism (hypothalamus / brainstem)	CNS	Central appetite suppression; reduced caloric intake
Gastric emptying delay	GI tract	Reduces postprandial glucose excursion
Weight loss (5–22%+ body weight)	Systemic	Reduces adiposity-driven inflammation; improves metabolic parameters
Anti-inflammatory effect	Systemic	Reduces CRP, IL-6, other inflammatory markers; partially independent of weight loss
Modest blood pressure reduction	Cardiovascular	~2–4 mmHg systolic reduction in trials
Cardioprotection (direct?)	Cardiovascular	GLP-1R expressed in cardiomyocytes; direct cardiac effects proposed but not established

The anti-inflammatory effect is of particular interest for aging biology. chronic-inflammation (inflammaging) is a primary driver of age-related morbidity. The reduction in CRP and IL-6 observed in SELECT and LEADER trials, partially independent of weight loss, suggests a direct immunomodulatory mechanism no-mechanism.

The relationship to deregulated-nutrient-sensing is indirect but real: weight loss reduces hyperinsulinemia, improving insulin sensitivity and normalizing insulin-igf1 signaling tone. Whether GLP-1R agonists modulate ampk or mtor directly (beyond the weight-loss effect) is contested unsourced.

Class member table

Agent	Type	Dosing	Primary approvals	Landmark aging-adjacent trial
Liraglutide	GLP-1 RA	Daily SC	T2D (2010), obesity (2014)	LEADER (MACE, T2D)
Semaglutide	GLP-1 RA	Weekly SC or oral	T2D (2017), obesity (2021)	SUSTAIN-6 (T2D); SELECT (non-diabetic CVD); STEP-HFpEF
Tirzepatide	GLP-1 / GIP dual agonist	Weekly SC	T2D (2022), obesity (2023)	SURMOUNT-1 (weight loss); SURPASS-CVOT (2025: non-inferior to dulaglutide on 3-pt MACE, superiority not met; post-hoc 6-component composite HR 0.84)
Retatrutide	GLP-1 / GIP / glucagon triple agonist	Weekly SC	Investigational	Phase 3 (2024–)
Exenatide	GLP-1 RA	Twice daily or weekly SC	T2D (2005)	EXSCEL (MACE, neutral)
Dulaglutide	GLP-1 RA	Weekly SC	T2D (2014)	REWIND (MACE, positive)
Lixisenatide	GLP-1 RA	Daily SC	T2D (EU 2013, US 2016)	ELIXA (MACE, neutral)

Tirzepatide’s dual GLP-1/GIP agonism produces greater weight loss than pure GLP-1 RAs (~20–22% vs ~15%); retatrutide (GLP-1/GIP/glucagon) may exceed this further. Whether greater weight loss translates to greater aging-biology benefit is unknown needs-human-replication.

Key aging-relevant trials

SELECT — Semaglutide, non-diabetic CVD (Lincoff 2023)

The most aging-relevant trial to date for this class ¹:

• Phase 3 RCT; n=17,604; adults with obesity (BMI ≥27) + established CVD; no diabetes
• Semaglutide 2.4 mg SC weekly vs placebo; median follow-up ~33 months
• Primary endpoint (MACE): HR ~0.80, representing ~20% relative risk reduction needs-replication (numerics unverified; single trial)
• Weight loss: ~9–10% body weight in semaglutide arm vs ~1% placebo
• Inflammatory markers: CRP reduced ~37% in semaglutide arm; the MACE benefit was not fully explained by weight-loss alone in mediation analyses (reported in companion analyses)
• Key aging-biology implication: MACE reduction in a non-diabetic population establishes that the class benefit is not limited to glycemic improvement — the cardiovascular and anti-inflammatory effects may be independently relevant to aging.

Dimension	Status
Pathway conserved in humans?	yes — GLP-1R is a human target; trial was conducted in humans
Phenotype conserved in humans?	yes — MACE is a human cardiovascular outcome
Replicated in humans?	yes (cardiovascular endpoint); no (aging-specific / frailty endpoint)

SUSTAIN-6 — Semaglutide in T2D (Marso 2016)

• Phase 3 RCT; n=3,297; adults with T2D + high CV risk
• Semaglutide 0.5 or 1.0 mg SC weekly vs placebo; median follow-up 2.1 years
• Primary endpoint (MACE): HR ~0.74 (~26% RRR); p<0.001 for non-inferiority; superiority p=0.02
• Includes T2D population — aging-biology relevance is partial (confounded by glycemic benefit)

SURMOUNT-1 — Tirzepatide, obesity (Jastreboff 2022)

• Phase 3 RCT; n=2,539; adults with obesity (BMI ≥30, or ≥27 with comorbidity); no T2D
• Tirzepatide 5 / 10 / 15 mg SC weekly vs placebo; 72 weeks
• Weight loss: 15 mg dose achieved ~22.5% body weight reduction vs ~2.4% placebo (mean ~21 kg absolute)
• The magnitude of weight loss is unprecedented in a pharmacological trial without bariatric surgery; implications for adiposity-driven aging biology are under study
• Muscle composition endpoints: body composition was measured (DXA/CT in subset) — lean mass loss was noted alongside fat mass loss; ratio not the primary endpoint needs-replication

STEP-HFpEF — Semaglutide in HFpEF + obesity (Kosiborod 2023)

• Phase 3 RCT; n=529; adults with HFpEF (EF ≥45%) + obesity (BMI ≥30)
• Semaglutide 2.4 mg SC weekly vs placebo; 52 weeks
• Co-primary endpoints: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and body weight
• KCCQ-CSS improved ~7 points more in semaglutide arm; body weight reduced ~13%
• HFpEF is an age-predominant, obesity-driven condition with poor pharmacological options; this trial represents one of the most clinically significant signals for the class in an aging-relevant phenotype
• See heart-failure for mechanism linkage

SOUL — Oral semaglutide in T2D + ASCVD/CKD (McGuire 2025)

R34 update (2026-05-08). McGuire et al. (NEJM 2025) reported the first dedicated CV-outcomes trial of oral semaglutide ²:

• Phase 3 RCT; n=9,650; T2D + atherosclerotic CVD, CKD, or both; age ≥50
• Once-daily oral semaglutide 14 mg vs placebo on top of standard care; mean follow-up 47.5 months
• Primary endpoint (3P-MACE): HR 0.86 (95% CI 0.77–0.96, p=0.006) — 14% relative risk reduction
• Major kidney disease events (5-point composite) did not reach significance
• Serious adverse events 47.9% semaglutide vs 50.3% placebo; GI disorders 5.0% vs 4.4%
• Establishes the cardioprotective effect generalizes across SC and oral semaglutide formulations; the effect magnitude is similar to SUSTAIN-6 (~14% in SOUL vs ~26% in SUSTAIN-6) but in a more intensively pre-treated contemporary T2D population

SUMMIT — Tirzepatide in obesity-related HFpEF (Packer 2025)

R34 update (2026-05-08). Packer et al. (JACC 2025) reported a prespecified diabetes-stratified analysis of SUMMIT ³:

• Phase 3 RCT; n=731; HFpEF + obesity (BMI ≥30); 1:1 tirzepatide ≤15 mg SC weekly vs placebo; median 104 weeks
• Primary composite (CV death + worsening HF events): HR 0.62 (95% CI 0.41–0.95, p=0.026) — driven primarily by reduction in worsening HF events
• Effect was consistent with vs without diabetes (Pinteraction=0.95): HR 0.64 with diabetes, 0.61 without
• Weight loss less in T2D arm (10.4% vs 12.9%, Pinteraction=0.04) but paracardiac fat decline and LV mass reduction equivalent — implying weight-loss magnitude does NOT fully predict HF benefit
• KCCQ-CSS, 6MWD, NYHA-class improvements equivalent across diabetes strata
• Hallmark relevance: Tirzepatide extends the GLP-1-class HFpEF benefit established by STEP-HFpEF (semaglutide) to the dual GLP-1/GIP agonist; the visceral-fat / LV-mass dissociation from weight loss suggests a substrate-direct mechanism overlapping with the empagliflozin cardiac-fuel-switch hypothesis

STEP-HFpEF age-spectrum (Pandey 2025) — efficacy in elderly patients

R34 update (2026-05-08). Pandey et al. (Eur J Heart Fail 2025) pooled STEP-HFpEF + STEP-HFpEF DM (n=1,145) and stratified by age (<55 / 55–64 / 65–74 / ≥75) ⁴:

• Efficacy preserved across all age strata for KCCQ-CSS (Pinteraction=0.80) and body weight (Pinteraction=0.41)
• 25.5% of pooled cohort were aged ≥75 (n=292) — a meaningfully large oldest-old subset relative to most CVOTs
• 6MWD, hsCRP, hierarchical composite endpoint also consistent across age strata
• Safety profile preserved across age groups — partly addresses the prior “oldest-old data scarce” concern in earlier rows of this page

This is the most directly aging-relevant subanalysis for the class to date: efficacy and safety preserved up to and including the ≥75 stratum in HFpEF + obesity. Does not address sarcopenia paradox (no separate lean-mass analysis), but the 6MWD result indicates net functional benefit despite any lean-mass loss in this disease cohort.

EVOKE / EVOKE+ — Semaglutide in early Alzheimer’s disease (Cummings 2026) — NEGATIVE

R34 update (2026-05-08). Cummings et al. (Lancet 2026) reported parallel Phase 3 trials of oral semaglutide 14 mg flexible-dose in amyloid-confirmed early AD ⁵:

• n=3,808 total (evoke 1,855 + evoke+ 1,953); ages 55–85; 156-week treatment
• Primary endpoint negative: CDR-SB change at week 104 difference −0.08 (p=0.57) evoke; 0.10 (p=0.46) evoke+
• Both trials discontinued for negative clinical outcome
• Hallmark/aging implication: the largest aging-rejuvenation-relevant Phase 3 endpoint failure for the GLP-1 class. Substantially weakens the GLP-1-as-AD-therapy hypothesis. Does NOT rule out:
  • Earlier-stage / preclinical AD prevention populations
  • Non-AD aging-cognition contexts
  • The cardioprotective + HFpEF benefits that remain robust
• Net effect: the class retains strong cardiometabolic + HFpEF support; loses the most prominent neurodegeneration-disease application; aging-cognition trials in non-AD healthy older adults remain untested

LEADER — Liraglutide in T2D (Marso 2016)

• Phase 3 RCT; n=9,340; adults with T2D + high CV risk; median age 64
• Liraglutide 1.8 mg SC daily vs placebo; median follow-up 3.8 years
• MACE HR ~0.87 (~13% RRR); also reduced all-cause mortality HR ~0.85
• First GLP-1 RA trial to show MACE benefit; established the class cardiovascular signal

STEP-1 — Semaglutide for weight management (Wilding 2021)

• Phase 3 RCT; n=1,961; adults with obesity (BMI ≥30) or overweight + comorbidity; no T2D
• Semaglutide 2.4 mg SC weekly vs placebo; 68 weeks
• Body weight reduced ~14.9% vs ~2.4% placebo
• Established semaglutide 2.4 mg as an obesity indication separate from its T2D dose; pivotal for Wegovy approval

Anti-inflammatory mechanism and hallmark intersections

The class’s anti-inflammatory effect is mechanistically undercharacterized at the cellular level but observationally robust ¹. Proposed nodes:

• Adipose tissue remodeling: weight loss reduces visceral adipose; visceral adipocytes are major sources of TNF-α, IL-6, and adipokines that drive systemic inflammation
• Direct GLP-1R signaling on immune cells: GLP-1R is expressed on macrophages and monocytes; GLP-1R agonism may shift macrophage phenotype toward M2 (anti-inflammatory) no-mechanism in humans
• NLRP3 inflammasome suppression: preclinical evidence of GLP-1R-mediated reduction in NLRP3 activity; needs-human-replication
• NF-κB pathway modulation: proposed from cell-line data; not established in humans unsourced

Hallmark mapping:

Hallmark	Link	Evidence level
chronic-inflammation	Direct — CRP/IL-6 reduction; MACE reduction partially independent of weight	Human RCT (strong)
deregulated-nutrient-sensing	Indirect — improved insulin sensitivity; reduced hyperinsulinemia; insulin-IGF1 axis normalization	Human RCT (moderate)
cellular-senescence	Speculative — adipose senescent cells reduced with weight loss?	Preclinical hypothesis only needs-human-replication
mitochondrial-dysfunction	Speculative — adiposity-driven mitochondrial stress may improve with weight loss	Preclinical needs-human-replication

Joint and cartilage — emerging OA chondroprotection hypothesis

A novel aging-relevant indication for the class, consolidating two preclinical-with-pilot-human-data publications (one liraglutide, one semaglutide) and one negative systemic-liraglutide RCT. The class evidence here is mixed: positive preclinical (rodent) and pilot-human signals exist, but a powered systemic-delivery human RCT for any GLP-1 RA in OA has either failed (liraglutide) or has not yet been conducted (semaglutide).

Negative human signal — Gudbergsen 2021 (systemic liraglutide)

Gudbergsen et al. 2021 (Am J Clin Nutr 113:314–323) reported a randomized controlled trial of daily systemic liraglutide injections after diet-induced weight loss in obese patients with knee OA ⁶. Liraglutide did NOT ameliorate OA-related pain. This is currently the only published Phase-2-equivalent human RCT for the class in OA. The Meurot 2022 group ⁷ interpreted this as a delivery-failure (poor joint penetration of systemic peptide) and pivoted to intra-articular delivery for their preclinical work — but the human-evidence consequence is that systemic liraglutide is currently a negative result for OA pain, and a successor systemic-RCT (semaglutide, tirzepatide) has not yet read out.

Positive preclinical — Meurot 2022 (intra-articular liraglutide)

Meurot et al. 2022 (Sci Rep 12:1567) demonstrated ⁷:

• GLP-1R protein expression in human OA articular cartilage and synovial membrane (IHC of n=6 OA arthroplasty patients) — first protein-level demonstration in OA-affected joint tissue
• IA liraglutide in the MIA mouse OA model: dose-dependent analgesia (EC50 = 11 µg) over 10–28 days; superior to dexamethasone 20 µg on pain endpoints; no body weight effect (local action)
• Reduced synovitis (Krenn score) significantly more than dexamethasone (p=0.0099 vs p=0.1288 NS)
• Tight synovitis-pain coupling (R²=0.91)
• In vitro IL-1β-stimulated chondrocytes and LPS-stimulated RAW 264.7 macrophages: dose-response IC50 = 38–58 nM for NO, PGE₂, IL-6, MMP-3, MMP-13, GAG release; mRNA reductions in iNos, Cox2, Tnf-α, Adamts4/5, Mmp-3/13
• M1→M2 macrophage repolarization (Mcp-1↓, Cd38↓, Erg-2↑)
• GLP-1R is the on-target receptor — exendin-9-39 (GLP-1R competitive antagonist) at 100 nM completely reverses anti-inflammatory effects of 50 nM liraglutide

Significant commercial COI: senior authors (Berenbaum, Rattenbach) are CEOs of 4P-Pharma + 4Moving Biotech and hold patents on GLP-1 analogs for OA. Independent replication required.

Positive preclinical + pilot RCT — Qin 2026 (systemic semaglutide, weight-loss-independent)

Qin et al. 2026 (Cell Metab 38:582–597) ⁸ — published online 2026-02-09, in print 2026-03-03 — reported:

• Semaglutide chondroprotection in obesity-OA mouse models (C57BL/6, male) — reduced cartilage degeneration, osteophyte formation, synovial lesion, pain sensitivity
• Diet-controlled experimental setting dissociates chondroprotection from weight loss — the central methodological contribution; effect persists when caloric intake is matched to controls (likely pair-feeding, specific protocol pending PDF verification)
• Mechanism: GLP-1R-AMPK-PFKFB3 axis — semaglutide → GLP-1R → AMPK activation → PFKFB3 downregulation → chondrocyte glycolysis-to-OXPHOS metabolic reprogramming → cartilage restoration under inflammatory conditions
• A randomized pilot clinical study (ChiCTR2200066291) is reported to support the findings; n, dose, duration, primary endpoint not in abstract — pending PDF verification

This is the first major demonstration of a weight-loss-independent chondroprotective mechanism for any GLP-1 RA in OA. It also reframes the systemic-delivery question — whether semaglutide’s PK/joint-distribution differs sufficiently from liraglutide to overcome the Gudbergsen 2021 systemic-failure barrier, or whether the obesity-OA mouse model does not extrapolate to typical-clinical OA, awaits a powered human RCT.

PDF NOT yet in a local paper archive (DOI not ingested by OpenAlex pipeline as of 2026-05-08). Quantitative claims (mouse n’s, dose, mg/kg, AMPK/PFKFB3 mechanism specifics — genetic KO vs pharmacologic, OXPHOS measurement modality) are abstract-only and require PDF cross-check before downstream-claim use. needs-pdf-verification

Hallmark mapping for OA application

Hallmark	Mechanism	Evidence quality
chronic-inflammation (joint)	Reduces synovitis, IL-6, PGE₂, NO; M1→M2 macrophage shift; GLP-1R-mediated 7	Mouse + in-vitro strong; human cartilage/synovium GLP-1R confirmed 7; no positive human RCT
deregulated-nutrient-sensing (chondrocyte)	AMPK activation → PFKFB3 ↓ → glycolysis-to-OXPHOS shift 8	Mouse + pilot RCT; abstract-only sourcing pending PDF
mitochondrial-dysfunction (chondrocyte fuel-switch)	Restored OXPHOS metabolism in OA chondrocytes 8	Mouse + pilot RCT; mechanism specifics PDF-unverified
cellular-senescence	Not directly tested; hypothesis-pending whether cartilage protection involves SASP attenuation	Untested in this class for OA no-mechanism

Open questions for the joint-cartilage indication

• contradictory-evidence — systemic liraglutide failed ⁶ but systemic semaglutide is reported positive in mice ⁸. Resolution requires a powered systemic-semaglutide OA RCT (or systemic-tirzepatide; or IA-formulation human work).
• needs-human-replication — Qin 2026 mechanism (GLP-1R-AMPK-PFKFB3) requires PDF cross-check and independent replication; the pilot RCT (ChiCTR2200066291) is single-center small-n.
• dose-response-unclear — what blood-level / joint-level concentration is required for chondroprotection vs systemic appetite suppression; the dose-response in mice may not predict human therapeutic window.
• needs-replication — Meurot 2022 has significant commercial COI; independent IA-liraglutide work is essential before clinical translation.

The sarcopenia paradox in older adults

A clinically significant concern for the aging population: GLP-1 RA-induced weight loss in older adults includes substantial lean mass (muscle) loss, which may worsen sarcopenia and frailty — the very aging phenotypes that would otherwise benefit from weight-related cardiovascular and metabolic improvements.

Locatelli et al. 2024 (Diabetes Care) ⁹ reviewed this directly:

• Incretin-based pharmacotherapy produces weight losses of ~15–24% body weight
• Approximately 10% of total weight loss (~6 kg absolute) is lean mass, not fat
• Resistance exercise training (>10 weeks, supervised) can recover ~3 kg lean mass
• Recommendation: pair GLP-1 RA therapy with supervised resistance training in older adults to preserve muscle; drug + exercise combination not yet tested in a powered aging-endpoint RCT needs-replication

The lean-mass-loss issue is not unique to GLP-1 RAs — it is a feature of any significant caloric deficit — but the magnitude and rapidity of GLP-1 RA-induced weight loss amplifies the risk in older, already-sarcopenic individuals.

In clinical practice for older adults:

• Pre-treatment assessment of muscle mass and physical function is recommended (gait speed, grip strength, DEXA if available)
• Protein intake monitoring (target >1.2 g/kg body weight/day) during treatment
• Resistance training cotherapy is evidence-based but logistics are challenging in frail older adults

This is the primary tension that makes GLP-1 RAs not simply beneficial in aging biology — the cardiovascular and anti-inflammatory benefits may be offset by accelerated functional decline due to muscle loss in the oldest and most frail patients. A dedicated aging RCT with both muscle-preserving and cardiovascular arms is needed. needs-human-replication

Class-level safety concerns

GI adverse effects

Nausea, vomiting, diarrhea, and constipation are dose-dependent and most prominent at initiation; typically attenuate over weeks. Dose-escalation protocols are designed to manage this. GI effects are the primary reason for discontinuation in trials (~5–10% discontinuation in placebo-controlled RCTs). Older adults may be more susceptible to GI-related dehydration and electrolyte disturbances.

Pancreatitis

Small absolute risk increase for acute pancreatitis (~0.1% absolute difference in most CVOTs); FDA Black Box Warning historically (subsequently moderated for some agents). Risk is real but low at population scale.

Thyroid C-cell tumors (liraglutide / semaglutide)

Rodent carcinogenicity signal (medullary thyroid carcinoma in rats at supratherapeutic doses); not established in humans. FDA contraindication in patients with personal/family history of medullary thyroid carcinoma or MEN2.

Muscle loss

Addressed in the sarcopenia paradox section above. Underdiscussed in the primary cardiovascular trial literature; increasingly recognized in obesity-medicine guidelines.

Cost and access

As of 2026, branded GLP-1 RAs (Wegovy, Zepbound) cost ~$1,000+/month in the US without insurance. This creates a severe equity barrier, especially relevant for aging-focused use where the greatest benefit population (older adults with obesity and cardiovascular disease) frequently has fixed incomes. Generic/biosimilar pipelines are in development but not yet widely available.

Translation gap assessment

Dimension	Status
Human cardiovascular outcomes data	Strong — multiple Phase 3 CVOTs (SELECT, LEADER, SUSTAIN-6)
Human weight-loss data	Strong — STEP-1, SURMOUNT-1, multiple trials
Human HFpEF data	Moderate — STEP-HFpEF (n=529; single trial) needs-replication
Aging-specific endpoint data (frailty, biological age)	None — not a primary endpoint in any completed trial needs-human-replication
Mechanism in aging biology (senescence, epigenetics)	Preclinical hypothesis only
Safety in oldest-old (age 80+)	Limited — CVOTs enrolled mostly age 50–75; oldest-old data scarce
Sarcopenia interaction	Recognized concern; no RCT with resistance training cotherapy powered for aging endpoints

The class occupies an unusual position in aging-biology pharmacology: it has the strongest human-evidence base of any investigational geroprotector class (strong MACE data; large trials; multiple agents), but its aging-specific evidence is entirely derived from cardiometabolic endpoints in disease populations, not from aging-endpoint trials in healthier older adults. The translation gap is not lack of human data — it is lack of the right kind of human data for aging-endpoint claims.

SENS / hallmark mapping

• Hallmark targets: chronic-inflammation (direct, human-trial-supported); deregulated-nutrient-sensing (indirect, via weight-mediated insulin sensitivity)
• SENS category: Not a primary SENS fit. SENS focuses on damage removal; GLP-1 RAs are more accurately a downstream phenotypic modifier that reduces the functional consequences of accumulated metabolic damage without repairing the upstream damage categories. Closest loose correspondence: AmyloSENS (if adipose amyloid or lipotoxic aggregates are a target) — but this is speculative and not established.

Clinical evidence status (as of 2026)

Trial	Agent	Population	Design	Key result	DOI
SELECT 1	Semaglutide 2.4 mg	Obesity + CVD, no T2D (n=17,604)	Phase 3 RCT	MACE ~20% RRR; CRP −37%	10.1056/NEJMoa2307563
STEP-HFpEF 10	Semaglutide 2.4 mg	HFpEF + obesity (n=529)	Phase 3 RCT	KCCQ-CSS +7 pts; weight −13%	10.1056/NEJMoa2306963
SURMOUNT-1 11	Tirzepatide 15 mg	Obesity, no T2D (n=2,539)	Phase 3 RCT	Weight −22.5%	10.1056/NEJMoa2206038
LEADER 12	Liraglutide 1.8 mg	T2D + high CV risk (n=9,340)	Phase 3 RCT	MACE HR 0.87; all-cause mortality HR 0.85	10.1056/NEJMoa1603827
SUSTAIN-6 13	Semaglutide 0.5/1.0 mg	T2D + high CV risk (n=3,297)	Phase 3 RCT	MACE HR 0.74	10.1056/NEJMoa1607141
STEP-1 14	Semaglutide 2.4 mg	Obesity, no T2D (n=1,961)	Phase 3 RCT	Weight −14.9%	10.1056/NEJMoa2032183

needs-human-replication — No trial has used aging-specific primary endpoints (frailty index, biological age clock, all-cause mortality in healthy adults 60+). All outcome evidence derives from cardiometabolic disease populations.

Limitations and open questions

• No aging-specific RCT. The critical gap: all positive human data comes from disease populations (T2D, obesity with CVD, HFpEF). Whether a healthy 65-year-old without established disease benefits from chronic GLP-1 RA use for aging endpoints is unknown. needs-human-replication
• Sarcopenia paradox unresolved. Lean mass loss with rapid weight reduction may cause net functional harm in already-sarcopenic older adults. The resistance-training cotherapy recommendation is evidence-based but operationally difficult and untested in aging-endpoint RCTs. needs-replication
• Long-term safety in older adults. Pivotal CVOTs enrolled mostly age 50–75; oldest-old (80+) data is sparse. GI adverse effects (aspiration risk, dehydration, electrolyte disturbance) may have greater consequences in frail older adults. long-term-unknown
• Anti-inflammatory mechanism incompletely characterized. The CRP/IL-6 reductions in SELECT are real but the cellular mechanism (adipose remodeling vs direct GLP-1R immune-cell signaling) is unresolved. Claims about NLRP3 or NF-κB modulation are preclinical only. no-mechanism
• Class heterogeneity vs class effect. Tirzepatide (dual GLP-1/GIP) and retatrutide (triple agonist) may have different aging-biology profiles than pure GLP-1 RAs. Treating this as a uniform class for aging endpoints may be premature. needs-replication
• Cost barrier. $1,000+/month cost limits real-world aging-endpoint trials and access equity. This is as much a health-systems problem as a biology problem.
• Optimal duration and dose for aging. Chronic use required to sustain effects; weight regain is rapid (~two-thirds of lost weight recovers within 12 months of stopping per STEP extension data). Lifelong therapy implications for an aging intervention are not established. dose-response-unclear

Cross-references

• semaglutide — verified-partial compound page (R21); SELECT and STEP trials
• liraglutide — compound page (stub); LEADER trial
• tirzepatide — compound page; SURMOUNT-1, SURPASS-CVOT
• type-2-diabetes — primary indication; verified-partial
• atherosclerosis — downstream target of MACE reduction; verified-partial
• heart-failure — STEP-HFpEF; verified-partial
• osteoarthritis — emerging joint/cartilage indication (R34 ad-hoc 2026-05-08); see “Joint and cartilage” section above
• chronic-inflammation — hallmark target; verified
• deregulated-nutrient-sensing — hallmark; indirect target via metabolic improvement; direct chondrocyte target via AMPK in ⁸
• mitochondrial-dysfunction — chondrocyte fuel-switch in ⁸
• sarcopenia — phenotype at risk from lean mass loss paradox
• meurot-2022-liraglutide-oa — IA liraglutide; MIA mouse; first GLP-1R protein-confirmation in human OA cartilage
• qin-2026-semaglutide-oa — systemic semaglutide; weight-loss-independent; GLP-1R-AMPK-PFKFB3 axis
• insulin-igf1 — pathway normalized by weight-loss-mediated insulin sensitivity improvement
• ampk — pathway; metformin comparison relevant here
• caloric-restriction — mechanistic overlap (reduced caloric intake); lifestyle comparator
• senomorphics — anti-inflammatory comparator class
• empagliflozin — alternative metabolic-rejuvenation pharmacotherapy (SGLT2 inhibitor class). Mechanistic overlap: caloric loss (glucosuria ~280 kcal/day) → CR-like AMPK activation → mTORC1 suppression. Differences: SGLT2 inhibitors drive ketogenesis (BHB → HDAC inhibition + NLRP3 dampening) without triggering the CNS satiety circuit; GLP-1 RAs drive central-mediated appetite suppression with greater weight-loss magnitude (15–25% vs ~3–4% for SGLT2i) but carry the muscle-mass-loss / sarcopenia paradox. CV mortality benefit established for both classes (EMPA-REG OUTCOME HR 0.62 for empagliflozin; SELECT MACE-RRR ~20% for semaglutide); no head-to-head aging-endpoint RCT.

Footnotes

Footnotes

1. doi:10.1056/NEJMoa2307563 · rct · n=17,604 · semaglutide 2.4 mg SC weekly vs placebo · obesity + established CVD, no T2D · median follow-up ~33 months · primary endpoint MACE ~20% RRR; CRP reduced ~37% · N Engl J Med 2023 · Lincoff AM et al. · archive: status pending (no local PDF) ↩ ↩² ↩³

2. doi:10.1056/NEJMoa2501006 · pmid:40162642 · rct · n=9,650 · McGuire DK et al. (SOUL Study Group) · N Engl J Med 2025;392:2001–2012 · oral semaglutide 14 mg daily vs placebo; T2D + ASCVD/CKD; mean follow-up 47.5 mo · MACE HR 0.86 (95% CI 0.77–0.96, p=0.006); kidney composite NS · archive: status pending ↩

3. doi:10.1016/j.jacc.2025.06.058 · rct · n=731 · Packer M et al. (SUMMIT Study Group) · J Am Coll Cardiol 2025;86:696–707 · tirzepatide ≤15 mg SC weekly vs placebo; HFpEF + obesity (BMI ≥30); median 104 wk · primary composite HR 0.62 (95% CI 0.41–0.95, p=0.026); effect consistent across diabetes strata · archive: status pending ↩

4. doi:10.1002/ejhf.70049 · pmid:41290376 · rct subanalysis (pre-specified) · n=1,145 (pooled STEP-HFpEF + STEP-HFpEF DM) · Pandey A et al. · Eur J Heart Fail 2025;27:2537–2543 · age-stratified efficacy of semaglutide 2.4 mg in HFpEF + obesity; 25.5% of cohort ≥75 yr · efficacy and safety preserved across all age strata · archive: PMC12765414 (OA) ↩

5. doi:10.1016/S0140-6736(26)00459-9 · pmid:41865758 · rct (two parallel Phase 3 trials) · n=3,808 (evoke 1,855; evoke+ 1,953) · Cummings JL et al. · Lancet 2026 (online ahead of print) · oral semaglutide 14 mg flexible-dose vs placebo; amyloid-confirmed early AD (mild MCI/mild dementia); 156 weeks · primary endpoint negative — CDR-SB change at week 104 difference −0.08 (p=0.57) evoke; 0.10 (p=0.46) evoke+; trials discontinued · archive: pending (Lancet OA) ↩

6. doi:10.1093/ajcn/nqaa328 · rct · n=156 · Gudbergsen H et al. · Am J Clin Nutr 2021;113:314–323 · “Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial” · negative — systemic liraglutide did NOT ameliorate OA-related pain in obese patients after diet-induced weight loss · cited from ⁷ (their reference 44); primary source not yet retrieved · the contemporary negative-systemic-delivery counterpoint to ⁸‘s positive-systemic-mouse claim ↩ ↩²

7. meurot-2022-liraglutide-oa · doi:10.1038/s41598-022-05323-7 · in-vivo (MIA mouse, n=120 short-term + n=49 long-term) + in-vitro (primary chondrocytes + RAW 264.7) + IHC of n=6 human OA arthroplasty samples · Meurot C et al. · Sci Rep 2022;12:1567 · IA liraglutide is analgesic (EC50 11 µg) + anti-synovitis + anti-catabolic; GLP-1R confirmed in human OA cartilage and synovium; M1→M2 macrophage repolarization; exendin-9-39 reverses (GLP-1R-on-target) · significant commercial COI (4P-Pharma + 4Moving Biotech CEOs; OA-GLP1 patents) · archive: downloaded; verified=true (PDF read end-to-end 2026-05-08) ↩ ↩² ↩³ ↩⁴ ↩⁵

8. qin-2026-semaglutide-oa · doi:10.1016/j.cmet.2026.01.008 · pmid:41666927 · in-vivo (C57BL/6 male obesity-OA mice; specific induction protocol pending PDF verification) + pilot RCT ChiCTR2200066291 · Qin H, Yu J, Yu H, et al.; corresponding Tong L, Chen D, Speakman JR, Zhang HT · Cell Metab 2026;38:582–597.e6 · weight-loss-independent chondroprotection via GLP-1R-AMPK-PFKFB3 axis; chondrocyte glycolysis→OXPHOS metabolic reprogramming · archive: PDF NOT in a local paper archive as of 2026-05-08 (DOI not yet ingested by OpenAlex); abstract + MeSH/keywords verified against PubMed efetch only · verified=false ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

9. doi:10.2337/dci23-0100 · review · incretin-based pharmacotherapy + resistance exercise; lean mass loss ~10% of total weight loss (~6 kg); resistance training >10 weeks recovers ~3 kg · Diabetes Care 2024 · Locatelli JC et al. · archive: closed-access (not_oa); no local PDF ↩

10. ↩
11. ↩
12. ↩

13. The first semaglutide CVOT trial, in T2D patients. ↩

14. ↩